In VivoIf you ask those involved, you may be led to believe that the use of organs on chips (OOCs) for drug development will become mainstream within the next couple of years. And there is some evidence to s
ScripLightstone Ventures has closed its third fund – its largest to date – with $375m to fund early stage biopharmaceutical and medical technology companies after several successful exits via initial publi